Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | ADCYAP1R1 | P41586 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366467 | 0.85 | MMP2 (0.60) | MAOBNR4A2MRGPRX4MAPK14 | |
| SCHEMBL16239839 | 0.82 | MAOB (0.67) | MAOBMRGPRX4FFAR1FFAR4MAPT | |
| SCHEMBL365474 | 0.82 | MAOB (0.67) | MAOBNR4A2MRGPRX4ADAMTS4MMP13 | |
| SCHEMBL366713 | 0.82 | RAB9A (0.57) | MAOBMRGPRX4MAPTHTTL3MBTL1 | |
| SCHEMBL4709035 | 0.82 | MAOB (0.77) | MAOBNR4A2MRGPRX4FFAR1FFAR4 | |
| SCHEMBL20463439 | 0.82 | MAOB (1.00) | MAOBNR4A2MRGPRX4FFAR1FFAR4 | |
| SCHEMBL365173 | 0.81 | MAOB (0.61) | MAOBNR4A2MAPTL3MBTL1 | |
| SCHEMBL680717 | 0.81 | MAPK14 (0.56) | MRGPRX4MAPTHTTMMP13MAPK14 | |
| SCHEMBL14014028 | 0.80 | NR4A2 (1.00) | MAOBNR4A2MRGPRX4FFAR1FFAR4 | |
| SCHEMBL22481025 | 0.80 | MRGPRX4 (1.00) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | MAOB 3660/4885NR4A2 1933/4885MRGPRX4 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.